Prime Medicine, Inc. (PRME) Announces NEJM Publication Of PM359 Data

Group 1 - Prime Medicine, Inc. (NASDAQ:PRME) is recognized as one of the 12 best genomics stocks to invest in [1] - The New England Journal of Medicine published Phase 1/2 clinical results for PM359, an experimental autologous hematopoietic stem cell therapy for p47phox chronic granulomatous condition, showing promising safety and effectiveness [2] - In the Phase 1/2 trial, two patients exhibited fast neutrophil engraftment with 69% and 83% dihydrorhodamine-positive neutrophils by Day 30, and no new CGD-related problems were reported post-infusion [2] Group 2 - LifeSci Capital initiated coverage of Prime Medicine, Inc. with an Outperform rating and a $6 price target, highlighting the company's potential in gene editing treatments for conditions with significant unmet demand [3] - The firm expressed optimism regarding the potential of Prime Medicine's treatments for Wilson's disease and alpha-1 antitrypsin deficiency [3] - Prime Medicine focuses on providing genetic medicines through gene editing technology known as Prime Editing [4]